The US Food and Drug Administration has approved tezepelumab for add-on maintenance treatment of adults and children aged 12 years and older with severe asthma. Tezepelumab, developed and marketed jointly by Amgen and AstraZeneca under the brand name Tezspire, is a first-in-class biologic therapy for severe asthma. The drug helps stop inflammation that causes asthma exacerbations by targeting thymic stromal lymphopoietin. Tezepelumab was cleared for patients’ use following an FDA priority review and approval was based on results of the PATHFINDER clinical trial program.